BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Amonafide L-malate: Completed Phase III enrollment

Antisoma completed enrollment of over 420 patients in the open-label, international Phase III ACCEDE trial comparing 600 mg/m 2 IV AS1413 given for 5 days plus cytarabine vs. daunorubicin plus cytarabine. Last year, Antisoma amended the primary endpoint...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >